MaxCyte (MXCT) (MXCT)
:MXCT
Top Page
MaxCyte
(MXCT)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.67
Action:ReiteratedDate:03/28/26
The score is pressured primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technicals (below major moving averages with negative MACD). Liquidity and cost reductions from the earnings update provide some support, but guidance points to continued near-term revenue pressure, and Nasdaq noncompliance adds additional risk.
Positive Factors
Strong cash position and no debt
A large cash balance with no net debt and a disclosed plan to retain at least $136M by year-end 2026 gives the company multi-quarter runway. This financial flexibility supports continued R&D, product launches, and absorption of revenue volatility without immediate financing, improving strategic optionality.
Negative Factors
Multi-year revenue decline
A sustained top-line decline that accelerated in 2025 reduces operating leverage and makes fixed-cost absorption harder despite strong gross margins. Continued revenue weakness limits cash generation and will prolong the path to operating profitability unless instrument placements, PA demand, or SPL program payments recover.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash position and no debt
A large cash balance with no net debt and a disclosed plan to retain at least $136M by year-end 2026 gives the company multi-quarter runway. This financial flexibility supports continued R&D, product launches, and absorption of revenue volatility without immediate financing, improving strategic optionality.
Read all positive factors
MaxCyte (MXCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$73.05M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees114
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding106,861,430
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit3.14
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$2.87Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MaxCyte Business Overview & Revenue Model
Company Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfect...
How the Company Makes Money
MaxCyte makes money primarily by providing its cell-engineering platform to customers through (1) product revenue and (2) partnership-related revenue tied to clinical and commercial progress of customer programs.
1) Platform sales and recurring c...
MaxCyte Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 33.03M | 38.63M | 41.29M | 44.26M | 33.89M |
| Gross Profit | 26.80M | 31.53M | 36.55M | 39.16M | 30.25M |
| EBITDA | -40.14M | -46.41M | -44.13M | -24.66M | -16.61M |
| Net Income | -44.63M | -41.05M | -37.92M | -23.57M | -19.08M |
Balance Sheet | |||||
| Total Assets | 202.51M | 239.47M | 268.27M | 286.65M | 284.12M |
| Cash, Cash Equivalents and Short-Term Investments | 103.04M | 154.48M | 168.29M | 227.34M | 255.04M |
| Total Debt | 17.94M | 18.03M | 18.74M | 16.09M | 5.68M |
| Total Liabilities | 31.02M | 33.22M | 36.11M | 32.69M | 21.22M |
| Stockholders Equity | 171.49M | 206.25M | 232.17M | 253.97M | 262.90M |
Cash Flow | |||||
| Free Cash Flow | -36.18M | -29.26M | -25.39M | -33.26M | -14.51M |
| Operating Cash Flow | -34.41M | -27.61M | -21.69M | -14.78M | -10.68M |
| Investing Cash Flow | 25.93M | 6.93M | 54.98M | -24.82M | -195.01M |
| Financing Cash Flow | 656.00K | 2.06M | 2.14M | 2.89M | 234.72M |
MaxCyte Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
MaxCyte Corporate Events
Business Operations and StrategyExecutive/Board Changes
MaxCyte Appoints New Chief Financial Officer Ahuja
Positive
Mar 27, 2026
On March 23, 2026, MaxCyte announced the appointment of Parmeet Ahuja as Chief Financial Officer and principal accounting officer, effective March 30, 2026, succeeding outgoing CFO Douglas Swirsky as part of a previously disclosed transition. Ahuj...
Business Operations and StrategyFinancial Disclosures
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
Negative
Mar 24, 2026
On March 24, 2026, MaxCyte reported fourth-quarter 2025 revenue of $7.3 million, down 16% year-on-year, and full-year 2025 revenue of $33.0 million, a 15% decline, mainly due to headwinds from select SPL customers, including a 15% reduction in pur...
Delistings and Listing ChangesRegulatory Filings and Compliance
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
Negative
Mar 20, 2026
On March 16, 2026, MaxCyte, Inc. disclosed it had received notice from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive trading days, putting it out of compliance with Nasdaq Global Select Mark...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.